Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel Meeting Abstract


Authors: Scher, H. I.; Heller, G.; Molina, A.; Kheoh, T. S.; Attard, G.; Moreira, J.; Sandhu, S. K.; Parker, C.; Logothetis, C.; McCormack, R. T.; Fizazi, K.; Anand, A.; Danila, D. C.; Fleisher, M.; Olmos, D.; Haqq, C. M.; De Bono, J. S.
Abstract Title: Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel
Meeting Title: 47th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 29
Issue: 18 Suppl.
Meeting Dates: 2011 Jun 3-7
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2011-06-20
Language: English
ACCESSION: WOS:000208865800020
PROVIDER: wos
DOI: 10.1200/jco.2011.29.18_suppl.lba4517
Notes: Meeting Abstract: LBA4517 -- Source: Wos
Altmetric Score
MSK Authors
  1. Glenn Heller
    303 Heller
  2. Ana Maria Luisa Molina
    45 Molina
  3. Martin Fleisher
    242 Fleisher
  4. Howard Scher
    835 Scher
  5. Daniel C Danila
    83 Danila
  6. Aseem Anand
    45 Anand